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Abstract
Background
Atrial fibrillation (AF) is the most common type of cardiac arrhythmia and is associated with
increased risk of stroke and congestive heart failure. Lead-I electrocardiogram (ECG)
devices are handheld instruments that can detect AF at a single-time point.
Purpose
To assess the diagnostic test accuracy, clinical impact and cost effectiveness of single-time
point lead-I ECG devices compared with manual pulse palpation (MPP) followed by a 12-
lead ECG for the detection of AF in symptomatic primary care patients with an irregular
pulse.
Methods
Electronic databases (MEDLINE, MEDLINE Epub Ahead of Print and MEDLINE In-Process,
EMBASE, PubMed and Cochrane Databases of Systematic Reviews, Cochrane Central
Database of Controlled Trials, Database of Abstracts of Reviews of Effects, Health Technol-
ogy Assessment Database) were searched to March 2018. Two reviewers screened the
search results, extracted data and assessed study quality. Summary estimates of diagnostic
accuracy were calculated using bivariate models. Cost-effectiveness was evaluated using
an economic model consisting of a decision tree and two cohort Markov models.
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Results
Diagnostic accuracy
The diagnostic accuracy (13 publications reporting on nine studies) and clinical impact
(24 publications reporting on 19 studies) results are derived from an asymptomatic popula-
tion (used as a proxy for people with signs or symptoms of AF). The summary sensitivity of
lead-I ECG devices was 93.9% (95% confidence interval [CI]: 86.2% to 97.4%) and sum-
mary specificity was 96.5% (95% CI: 90.4% to 98.8%).
Cost effectiveness
The de novo economic model yielded incremental cost effectiveness ratios (ICERs) per
quality adjusted life year (QALY) gained. The results of the pairwise analysis show that all
lead-I ECG devices generate ICERs per QALY gained below the £20,000-£30,000 thresh-
old. Kardia Mobile is the most cost effective option in a full incremental analysis. Lead-I ECG
tests may identify more AF cases than the standard diagnostic pathway. This comes at a
higher cost but with greater patient benefit in terms of mortality and quality of life.
Limitations
No published data evaluating the diagnostic accuracy, clinical impact or cost effectiveness
of lead-I ECG devices for the target population are available.
Conclusions
The use of single-time point lead-I ECG devices in primary care for the detection of AF in
people with signs or symptoms of AF and an irregular pulse appears to be a cost effective
use of NHS resources compared with MPP followed by a 12-lead ECG, given the assump-
tions used in the base case model.
Registration
The protocol for this review is registered on PROSPERO as CRD42018090375.
Introduction
Atrial fibrillation (AF) is a disturbance in heart rhythm (arrhythmia) caused by abnormal elec-
trical activity in the upper chambers of the heart (atria).[1] AF is the most common type of
arrhythmia. Estimates from 2010 suggest that 20.9 million men and 12.6 million women
worldwide are living with AF.[2] The median age of diagnosis is 75 years with the highest
number of cases between the ages of 75 to 79 years in males and 80 to 84 years in females.[3]
AF can be paroxysmal (intermittent episodes lasting less than 7 days that stop without treat-
ment), persistent (episodes lasting longer than 7 days and do not terminate without treatment)
or permanent (present all the time). AF can be categorised as valvular or non-valvular depend-
ing on the underlying cause (i.e. whether valve disease is present or not). Both valvular and
non-valvular AF can be paroxysmal, persistent or permanent.[4] Patients diagnosed with par-
oxysmal AF may develop persistent or permanent AF.[2] It is possible, but unusual, for some
people with persistent AF to revert to normal sinus rhythm.[2]
Patients with AF may experience palpitations, dizziness, shortness of breath and tiredness.
However, AF can be asymptomatic and may only be identified when people attend medical
Lead-I ECG for detecting AF in patients with an irregular pulse
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appointments for other conditions. Due to its intermittent nature, many cases of paroxysmal
AF remain undiagnosed.[2] Cases of paroxysmal AF may only be detected with prolonged
monitoring, rather than by a single examination.[2]
The National Institute for Health and Care Excellence (NICE)[5] recommends that, after
positive manual pulse palpation (MPP), an AF diagnosis should be confirmed with an electro-
cardiogram (ECG). People who present to primary care with signs or symptoms of AF and an
irregular pulse should be referred for a 12-lead ECG in the days following their primary care
appointment if a 12-lead ECG is not available in the practice. Treatment (where indicated)
begins following the results of the 12-lead ECG test. Lead-I ECG devices are handheld instru-
ments that can be used to detect AF. Lead-I ECGs are so-called because of the 12-lead ECG
that they simulate (i.e. Lead-I) rather than the fact that they record "one lead" only. They could
be used to detect AF during a primary care appointment in people who present with signs or
symptoms and have an irregular pulse, which may reduce the time to initiating anticoagulation
therapy.
Objectives
The aim of this study was to assess the diagnostic test accuracy, the clinical impact and the cost
effectiveness of single-time point lead-I ECG devices for the detection of AF in people present-
ing to primary care with signs or symptoms of AF and who have an irregular pulse, compared
with MPP followed by a 12-lead ECG in primary or secondary care (prior to initiation of antic-
oagulation therapy). To achieve this aim we:
1. conducted systematic reviews of the diagnostic accuracy and clinical impact of lead-I ECG
devices for (1) detecting AF in people presenting to primary care with signs or symptoms of
AF, or, if evidence was not available for this population/setting, for (2) detecting AF in an
asymptomatic population defined as people presenting to any setting without symptoms of
AF, with or without a previous diagnosis of AF
2. developed an economic model to assess the cost effectiveness of single-time point lead-I
ECG devices compared with MPP followed by a 12-lead ECG in primary or secondary care
in people presenting to primary care with signs or symptoms of AF who have an irregular
pulse.
Methods: Assessment of clinical impact and diagnostic test
accuracy
The systematic review methods followed the general principles outlined in the Centre for
Reviews and Dissemination (CRD) guidance for conducting reviews in health care,[6] the
NICE Diagnostics Assessment Programme manual[7] and the Cochrane Handbook for Sys-
tematic Reviews of Diagnostic Test Accuracy.[8] The systematic review was conducted accord-
ing to a prespecified protocol[4] and is registered on PROSPERO as CRD42018090375. The
systematic review is reported in accordance with the Preferred Reporting Items for Systematic
Reviews and Meta-Analyses (PRISMA) for diagnostic test accuracy (DTA) studies.[9] The
PRISMA-DTA checklist and PRISMA-DTA for abstracts checklist are presented in S1 and S2
Tables respectively.
Data sources and searches
Electronic databases (MEDLINE, MEDLINE Epub Ahead of Print and MEDLINE In-Process,
EMBASE, PubMed and Cochrane Databases of Systematic Reviews, Cochrane Central
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Database of Controlled Trials, Database of Abstracts of Reviews of Effects, Health Technology
Assessment Database) were searched up to 9th March 2018. The search strategy used for the
MEDLINE database is presented in S1 Text. The MEDLINE search strategy was adapted to
enable similar searches of the other relevant electronic databases.
The search results were managed using EndNote X8 software. The reference lists of relevant
systematic reviews and eligible studies were hand-searched to identify further potentially rele-
vant studies.
Study selection
The citations identified were assessed for inclusion in the review using a two-stage process.
First, two reviewers independently screened all titles and abstracts identified by the electronic
searches to identify potentially relevant articles to be retrieved. Second, full-text copies of these
studies were obtained and assessed independently by two reviewers for inclusion using the eli-
gibility criteria outlined in S3 Table. Any disagreements were resolved through discussion at
each stage, and, if necessary, in consultation with a third reviewer. Studies that assessed the
diagnostic accuracy of lead-I ECG devices used at a single-time point to detect AF in an
asymptomatic population were considered for inclusion due to the absence of studies in symp-
tomatic populations. We considered an asymptomatic population to comprise people not pre-
senting with symptoms of AF, with or without a previous diagnosis of AF.
Data extraction
Data were extracted relating to the information described in S3 Table. Data extraction was car-
ried out by one reviewer and checked for accuracy by a second reviewer. Any disagreements
were resolved through discussion, and, if necessary, in consultation with a third reviewer.
Quality assessment
The methodological quality of the included diagnostic accuracy studies was assessed using the
QUality Assessment of Diagnostic Accuracy Studies—2 (QUADAS-2) tool tailored to the
review question.[10] The methodological quality of cross-sectional and case-controlled studies
evaluating the clinical impact of lead-I ECG devices was assessed using the Newcastle-Ottawa
quality assessment scale.[11, 12]
Quality assessment of the included studies was undertaken by one reviewer and checked by
a second reviewer. Any disagreements were resolved by discussion, and, if necessary, in con-
sultation with a third reviewer.
Data synthesis and analysis
The sensitivity and specificity of each index test were summarised in forest plots and plotted in
receiver operating characteristic (ROC) space. Pooled estimates of sensitivity and specificity
with 95% confidence intervals (CIs) were obtained using bivariate models.[13] The bivariate
model was fitted using the metandi and xtmelogit commands in Stata version 14. Summary
receiver operating characteristic (SROC) plots were produced using RevMan 5.3. When there
were few studies, the bivariate model was reduced to two univariate random effect logistic
regression models by assuming no correlation between sensitivity and specificity across stud-
ies.[14] When little or no heterogeneity was observed on forest plots and SROC plots, the mod-
els were further simplified into fixed effect models by eliminating the random effects
parameters for sensitivity and/or specificity.[14] Judgement of heterogeneity was based on the
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visual appearance of forest plots and SROC plots in addition to clinical judgement regarding
potential sources of heterogeneity.
The analyses were stratified by whether diagnosis of AF was made by a trained healthcare
professional interpreting the lead-I ECG trace, or by the lead-I ECG algorithm. For both sets
of analyses, the reference standard was interpretation of the 12-lead ECG trace by a trained
healthcare professional. When studies reported data for two types of lead-I ECG device and
two different interpreters, one dataset was chosen and sensitivity analyses were performed
using the alternative datasets. Clinical impact outcomes were synthesised narratively.
Methods: Assessment of cost effectiveness
A de novo economic analysis was undertaken following the diagnostic pathway for patients
presenting to primary care with signs or symptoms of AF and an irregular pulse. Results were
presented over a time horizon of 30 years with patients entering the model at age 70. The eco-
nomic evaluation took a NHS/Personal Social Services (PSS) perspective. The economic evalu-
ation is only relevant to primary care practices where patients have to wait at least 48 hours
between an initial consultation with the GP and having a 12-lead ECG; this allows the benefit
of early anticoagulation and rate control treatment for those patients who receive a positive
lead-I ECG to be considered. The base case model assumptions are presented in S5 Table.
Model structure
A decision tree and two cohort Markov models were built in Microsoft Excel1 (Microsoft
Corporation, Redmond, WA, USA). The decision tree describes the pathway that a patient pre-
senting to primary care with signs or symptoms of AF and an irregular pulse follows in the ini-
tial GP consultation (S1–S3 Figs). The first Markov model captured the differences in the costs
and benefits of treatment (standard diagnostic pathway outlined in NICE CG180 versus lead-I
ECG pathway) during the first 3 months after the initial appointment (S4 Fig). During this
period, some patients will be diagnosed with AF and start treatment whilst other patients will
have further tests to diagnose or rule out AF (where ‘rule out’ means no diagnosis of AF is
recorded and no treatment for AF is started). The second Markov model captured the differ-
ences in lifetime costs and benefits after patients have either received a diagnosis of AF or have
had AF ruled out (S5 Fig). Patients remained in the second Markov model until death. The
cycle length was 3 months in the second Markov model. Costs and benefits were discounted at
3.5% per year.
Patient population
The modelled population was people with signs or symptoms of AF plus an irregular pulse.
This population includes patients with AF and patients without AF who are similarly symp-
tomatic. Estimates of the prevalence of AF by age and sex were taken from a paper by Adder-
ley;[15] these age-sex specific prevalence estimates are based on the results of a study carried
out using primary care records from UK general practice in 2016.
The proportion of patients with AF who are symptomatic was taken from an observational
cohort study of data from the US Outcomes Registry for Better Informed Treatment of Atrial
Fibrillation (ORBIT-AF registry) by Piccini;[16] the study reports that women with AF were
more likely to be symptomatic than men (67.9% versus 57.5%).
The proportion of patients with symptomatic undiagnosed AF who have paroxysmal AF
could not be found in the literature. A fixed-effects meta-analysis published by Welton[17]
reported that the proportion of patients with paroxysmal AF (not explicitly symptomatic) var-
ied substantially between the studies[18–20] included in the meta-analysis (from 0.059 to
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0.835). Given the wide range reported by Welton[17] and the lack of evidence specifically on
incidence rates for symptomatic paroxysmal AF, it was assumed in our base case that 50% of
patients in the model with AF would have paroxysmal AF.
Tests and treatments
Cost per lead-I ECG test was calculated as the annual cost per device divided by the number of
patients in the eligible population per year plus any extra costs associated with each use of the
device (S5A and S5B Table). Costs for the 12-lead ECG tests were estimated using a microcost-
ing approach for 12-lead ECG tests carried out in primary care and using NHS Reference
Costs for tests carried out in secondary care (S6 Table). The proportion of patients receiving
anticoagulation for AF was estimated using data from the Quality and Outcomes Framework
2016/2017 (AF007).[21] Apixaban was used as the basis for modelling costs and outcomes for
all patients receiving anticoagulant therapy.
Mortality, cardiovascular events and adverse events
Age- and sex-adjusted mortality rates were estimated for patients with and without AF who
were and were not receiving anticoagulant therapy, and who had not experienced a previous
cardiovascular event (CVE) (S7 Table). Mortality risk for patients who experienced a subse-
quent CVE was assumed to be 2.6 times greater than mortality risk for patients with no history
of CVEs, based on the results of a study of stroke survivors in Norway.[22] The CVEs included
in the model were: ischaemic stroke, transient ischaemic attack and haemorrhagic stroke. Clin-
ically relevant bleeds were considered to be adverse events (AEs). Rates for CVEs depended on
AF- and treatment status, and whether a patient had experienced a previous CVE. Rates for
AEs depended on AF- and treatment status but did not take account of the history of previous
events (S8A–S8E Table).
Utilities
Utility values for the symptomatic and asymptomatic AF-positive population were based on a
study by Berg.[23] Berg provides the coefficients of regression models fitted to the results of
the EQ-5D-3L[24] questionnaire completed as part of a large European survey of patients with
AF. Mean age-specific utility values for symptomatic patients with AF were calculated using
the coefficients from the study by Berg[23] and adjusted for model age, sex ratio and symptom
proportions.
Analysis of uncertainty
Probabilistic sensitivity analysis (PSA) results were presented to reflect uncertainty in the
model inputs; extensive deterministic sensitivity analysis and scenario analysis were also car-
ried out to assess the impact of uncertainty in model assumptions. We report the total costs of
the annual number of symptomatic patients with positive MPP seen by a single GP, total qual-
ity adjusted life years (QALYs) for these patients, incremental costs and QALYs, and incre-
mental cost effectiveness ratios (ICERs).
Results
The electronic database searches identified 1151 citations (915 unique records). No studies
were identified for the population of interest (i.e. people with signs or symptoms of AF and
who have an irregular pulse). Therefore, all the studies included in the systematic reviews
assessed the diagnostic accuracy and clinical impact of lead-I ECG devices used at a single-
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time point to detect AF were performed in an asymptomatic population. The PRISMA[25]
flow chart detailing the screening process for the review is shown in Fig 1. Studies excluded at
the full-text paper screening stage with reasons for exclusion are presented in S2 Text.
Diagnostic test accuracy
We identified 13 publications[26–38] reporting on nine studies. In these studies, the index test
(lead-I ECG device) was interpreted by the device algorithm or by a trained healthcare profes-
sional, including cardiologists, electrophysiologists and general practitioners. All studies used
a 12-lead ECG device interpreted by a trained healthcare professional as the reference stan-
dard. The characteristics of the nine included diagnostic test accuracy studies are summarised
in Table 1. All studies were assessed for risk of bias and applicability using the QUADAS-2
tool[10] and a summary of the results is presented in S9 Table.
Interpreter of lead-I ECG: Trained healthcare professional
Data from four studies[28, 29, 31, 36] contributed to the meta-analyses (two studies of Kardia
Mobile,[31, 36] one study of Zenicor-ECG[29] and one study of MyDiagnostick and Kardia
Mobile).[28] The main meta-analysis (number of AF cases = 118, total N = 580), indicated that
the pooled sensitivity of lead-I ECG devices was 93.9% (95% CI: 86.2% to 97.4%) and pooled
specificity was 96.5% (95% CI: 90.4% to 98.8%) (Fig 2). The SROC plot which shows the indi-
vidual study results as well as the meta-analysis result is presented in S6A Fig. Across the sensi-
tivity analyses, numerical results were similar; pooled sensitivity values ranged from 89.8% to
94.3% and pooled specificity values ranged from 95.6% to 97.4%.
Fig 1. PRISMA flow chart.
https://doi.org/10.1371/journal.pone.0226671.g001
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Table 1. Characteristics of studies included in the diagnostic test accuracy review.
Study Study design;
country and
setting
Population; number in analysis
and recruitment details
Age; sex and risk
factors for AF
Lead-I ECG
device
Interpreter of lead-I ECG Test sequence
Crockford
2013[37]
Cross-sectional;
UK; secondary
care
Patients referred to an
electrophysiology department;
N = 176; NR
Age; sex and risk
factors: NR
RhythmPad GP Algorithm 12-lead ECG followed
by lead-I ECG
Desteghe
2017[28]
Case-control;
Belgium; tertiary
care
Inpatients at cardiology ward;
N = 265; NR
Mean age ± SD (years):
67.9 ± 14.6
Sex: 138 (43.1%) female
Pacemaker: 4/55 (7.3%)
were intermittently
paced, and 18/55
(32.7%) were not being
paced during the
recordings
Known AF: 114/320
(35.6%)
AF at time of study:
11.9% on 12-lead ECG;
3.4% of all patients
admitted because of
symptomatic AF
Paroxysmal AF: 54.4%
MyDiagnostick
and Kardia
Mobile
Algorithm and two
electrophysiologists (results
presented separately for
algorithm and two
electrophysiologists)
12-lead ECG followed
by lead-I ECG (order
for the use of the
different lead-I ECG
tests not specified)
Doliwa
2009[29]
Case-control;
Sweden;
secondary care
People with AF, atrial flutter or
sinus rhythm; N = 100; patients
were recruited from a
cardiology outpatient clinic
Age; sex and risk
factors: NR
Zenicor-ECG Cardiologist 12-lead ECG followed
by lead-I ECG
Haberman
2015[31]
Case-control;
USA;
community and
secondary care
Healthy young adults, elite
athletes and cardiology clinic
patients; N = 130; NR�
Mean age ± SD (years):
59 ± 15
Sex: 73 (56%) male
Risk factors: NR
Kardia Mobile Electrophysiologist Lead-I ECG followed
by 12-lead ECG
Koltowski
2017[38]
Cross-sectional;
Poland; tertiary
care
Patients in a tertiary care
centre; N = 100; NR
Age; sex and risk
factors: NR
Kardia Mobile Cardiologist Lead-I ECG followed
by 12-lead ECG
Lau 2013
[33]
Case-control;
Australia;
secondary care
Patients at cardiology
department; N = 204; NR
Age and sex: NR
Known AF: 48 (24%)
Kardia Mobile Algorithm Lead-I ECG followed
by 12-lead ECG
Tieleman
2014[34]
Case-control;
Netherlands;
secondary care
Patients with known AF and
patients without a history of AF
attending an outpatient
cardiology clinic or a
specialised AF outpatient clinic;
N = 192; random selection of
patients due to have a 12-lead
ECG
Mean age ± SD (years):
69.4 ± 12.6
Sex: 48.4% male
Risk factors: NR
MyDiagnostick Algorithm Lead-I ECG followed
by 12-lead ECG
Vaes 2014
[35]
Case-control;
Belgium;
primary care
Patients with known AF and
patients without a history of
AF; N = 181; GP invitation
Mean age ± SD (years):
74.6 ± 9.7
Sex: 91 (48%) female
Known AF: 151
(83.4%)
MyDiagnostick Algorithm Lead-I ECG followed
by 12-lead ECG
Williams
2015[36]
Case-control;
UK; secondary
care
Patients with known AF
attending an AF clinic and
patients with AF status
unknown who were attending
the clinic for non-AF related
reasons; N = 95; patients
attending clinic appointments
who were due to have a 12-lead
ECG
Age; sex and risk
factors: NR
Kardia Mobile Cardiologist and general
practitioner with an interest
in cardiology
12-lead and lead-I
ECG carried out
simultaneously
AF = atrial fibrillation; ECG = electrocardiogram; GP = general practice; NR = not reported; SD = standard deviation
�Community population not included in the analysis as these comprised healthy young adults and elite athletes; only secondary care patients were included in the
analysis
https://doi.org/10.1371/journal.pone.0226671.t001
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Interpreter of lead-I ECG: Algorithm
Data from four studies[28, 33–35] were included in the meta-analyses (two studies of MyDiag-
nostick,[34, 35] one study of Kardia Mobile,[33] and one study MyDiagnostick and Kardia
Mobile).[28] Meta-analysis (number of AF cases = 219, total N = 842) showed a pooled sensi-
tivity of 96.2% (95% CI: 86.0% to 99.0%) and pooled specificity was 95.2% (95% CI: 92.9% to
96.8%). SROC plot is presented in S6B Fig. Numerical results were similar across the sensitivity
analyses; pooled sensitivity values ranged from 88.0% to 96.2% and pooled specificity values
ranged from 94.4% to 97.2%.
A summary of the results from the meta-analyses are presented in Table 2.
Clinical impact
We identified 24 publications[26–34, 38–52] reporting on 19 studies with a total of 33,993 par-
ticipants. The index tests evaluated included ImPulse (one study),[50] Kardia Mobile (12 stud-
ies), [31, 33, 38, 40, 41, 43, 44, 46, 48, 49, 51, 52] MyDiagnostick (four studies),[34, 39, 45, 47]
Zenicor ECG (one study)[29] and MyDiagnostick and Kardia Mobile (one study).[28] Test
failure rate was reported in nine studies[28, 31, 39, 43, 44, 47–50] and ranged from 0.1% to 9%.
Results for test failure rate included both failure of the lead-I ECG algorithm to produce a
result and poor quality of the lead-I ECG trace. Diagnostic yield was reported in 13 studies.[28,
34, 39, 41, 43–49, 51, 52] The percentage of new patients diagnosed with AF ranged from 0.4%
to 5.8%. Data for this outcome were considered too heterogeneous for a pooled estimate to be
clinically meaningful. Only one study[28] reported the concordance between lead-I ECG
devices (Kardia Mobile and MyDiagnostick) observing no difference in agreement between
the devices. Two studies[46, 48] reported a change in treatment management following the use
of the Kardia Mobile lead-I ECG in new patients diagnosed with AF. Acceptability of lead-I
ECG devices was reported in four studies,[41, 45, 46, 49] with generally positive views from
patients and healthcare staff. Full clinical impact results and quality assessment of studies
included is presented in the study monograph.[53]
Cost effectiveness
Four base case scenarios were investigated to estimate cost effectiveness depending on the
waiting times for a 12-lead ECG test (2 days or 14 days) and the location of the 12-lead ECG
test (primary or secondary care). Pairwise cost effectiveness results assuming the 12-lead ECG
was carried out in primary care and 2 days to 12-lead ECG (Base Case 1) for each index test
versus the standard diagnostic pathway are presented in Table 3 and incremental analysis
results are shown in Table 4. Costs and QALYs generated in Base Case 1 are shown in S10A
and S10B Table. Results for the other three base case scenarios are presented in S11A–S11L
Table.
Fig 2. Forest plot of individual studies included in the meta-analysis of all lead-I ECG devices (trace interpreted by a trained healthcare professional).
CI = confidence interval; EP1 = electrophysiologist 1; FN = false negative; FP = false positive; TN = true negative; TP = true positive.
https://doi.org/10.1371/journal.pone.0226671.g002
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The results of the pairwise analysis show that all lead-I ECG tests generated ICERs per
QALY gained below the £20,000-£30,000 threshold usually considered to be cost effective by
NICE. Kardia Mobile was the most cost effective option out of all the lead-I ECG tests included
in the analysis, as it cost less and generated more benefits than each of the other devices. Sce-
nario analyses were undertaken to investigate the impact on the ICER per QALY gained of
varying some of the base case assumptions. Scenario analyses are presented in S1 Scenarios.
Each lead-I ECG test identified more AF cases than the standard diagnostic pathway. This
came at a higher cost but with greater overall patient benefit in terms of mortality and quality
of life. More patients were diagnosed following a lead-I ECG test due to the assumption that
Table 2. Results from meta-analyses of lead-I ECG devices.
Data input from the Desteghe� and
Williams�� studies
Lead-I ECG device (# studies) in the meta-
analyses
# AF
cases
N Pooled sensitivity (95%
CI)
Pooled specificity (95%
CI)
Lead-I ECG trace interpreted by a trained healthcare professional (main analysis)
Kardia Mobile device and EP1� and
cardiologist�� data
Kardia Mobile (3), Zenicor-ECG (1) 118 580 93.9% (86.2% to 97.4%) 96.5% (90.4% to 98.8%)
Lead-I ECG trace interpreted by a trained healthcare professional (sensitivity analyses, cardiologist data��)
MyDiagnostick device and EP1� data Kardia Mobile (2), Zenicor-ECG (1),
MyDiagnostick (1)
118 582 90.8% (83.8% to 95.0%) 95.6% (89.4% to 98.3%)
MyDiagnostick device and EP2 data Kardia Mobile (2), Zenicor-ECG (1),
MyDiagnostick (1)
118 582 89.8% (82.7% to 94.1%) 96.8% (90.6% to 99.0%)
Kardia Mobile device and EP2� data Kardia Mobile (3), Zenicor-ECG (1) 120 584 91.8% (85.1% to 95.7%) 97.1% (90.8% to 99.1%)
Lead-I ECG trace interpreted by a trained healthcare professional (sensitivity analyses, GP data��)
Kardia Mobile device and EP1� and GP�� data Kardia Mobile (3), Zenicor-ECG (1) 118 580 94.3% (87.9% to 97.4%) 96.0% (85.4% to 99.0%)
Lead-I ECG trace interpreted by a trained healthcare professional (sensitivity analyses, Kardia Mobile)
Kardia Mobile device and EP1� data Kardia Mobile (3) 67 480 94.0% (85.1% to 97.7%) 96.8% (88.0% to 99.2%)
Kardia Mobile device and EP2� data Kardia Mobile (3) 69 484 91.3% (82.0% to 96.0%) 97.4% (88.3% to 99.5%)
Lead-I ECG trace interpreted by lead-I ECG device algorithm alone
MyDiagnostick device� data Kardia Mobile (1), MyDiagnostick (3) 219 842 96.2% (86.0% to 99.0%) 95.2% (92.9% to 96.8%)
Kardia Mobile device� data Kardia Mobile (2), MyDiagnostick (2) 219 842 95.3% (70.4% to 99.4%) 96.2% (94.2% to 97.6%)
MyDiagnostick device only MyDiagnostick (3) 171 638 95.2% (79.0% to 99.1%) 94.4% (91.9% to 96.2%)
Kardia Mobile device only Kardia Mobile (2) 70 469 88.0% (32.3% to 99.1%) 97.2% (95.1% to 98.5%)
# = number of; AF = atrial fibrillation; CI = confidence interval; EP1 = electrophysiologist 1; EP2 = electrophysiologist 2; GP = general practitioner
�From the Desteghe study27
��From the Williams study35
https://doi.org/10.1371/journal.pone.0226671.t002
Table 3. Base Case 1: Pairwise cost effectiveness analysis.
Strategy Costs QALYs Incremental costs Incremental QALYs ICER/ QALY gained
Standard pathway £514,187 447.963
Kardia Mobile £515,551 449.249 £1,364 1.286 £1,060
imPulse £530,745 448.987 £16,557 1.024 £16,165
MyDiagnostick £521,233 449.024 £7,046 1.061 £6,638
Generic lead-I device £516,730 449.246 £2,543 1.284 £1,981
Zenicor-ECG £518,468 449.199 £4,281 1.236 £3,462
RhythmPad GP� £518,436 448.573 £4,249 0.610 £6,962
ICER = incremental cost effectiveness ratio; QALY = quality adjusted life year
�Algorithm interpretation
https://doi.org/10.1371/journal.pone.0226671.t003
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patients with paroxysmal AF would be in AF at the time of the initial consultation and that this
would be captured by the lead-I ECG test. Some patients with paroxysmal AF would not be in
AF at the time of a 12-lead ECG in the standard diagnostic pathway and so would remain
undiagnosed. The extra cost of the lead-I pathway was primarily due to more patients receiving
anticoagulant treatment, which was offset substantially but not entirely by a decrease in CVE
rate (due to more patients with AF receiving treatment) and the associated lower cost of treat-
ing CVEs, particularly strokes. Lead-I ECGs were also associated with greater patient benefit
in terms of lower mortality and higher quality of life as a result of experiencing fewer CVEs.
This benefit may be reduced marginally by increased risk of clinically relevant bleeds due to
more people receiving anticoagulant therapy. There was some extra cost and benefit associated
with diagnosing patients more quickly than in the standard diagnostic pathway, but these were
minimal.
Discussion
No studies were identified that evaluated the diagnostic accuracy or the clinical impact of lead-
I ECG devices in people presenting to primary care with signs or symptoms of AF and an
irregular pulse. Consequently, the review focused on an asymptomatic population as pre-speci-
fied in the protocol.[4] We considered an asymptomatic population to comprise people not
presenting with symptoms of AF, with or without a previous diagnosis of AF. These patients
could have had co-existing cardiovascular conditions or could have been attending a cardio-
vascular clinic but did not present with signs or symptoms of AF. It is plausible that, if the pop-
ulation in the review had been people with signs or symptoms of AF and an irregular pulse,
the sensitivity of lead-I ECG devices where the trace was interpreted by a trained healthcare
professional would have been higher. However, it is also plausible that, in such a population,
the specificity of lead-I ECG devices where the trace was interpreted by a trained healthcare
professional would have been lower.
In the included studies, the sensitivity of lead-I ECG devices ranged from 80% to 100% and
specificity ranged from 76% to 99% when the lead-I ECG trace was interpreted by a trained
healthcare professional. The sensitivity results from the meta-analyses of lead-I ECG traces
interpreted by a trained healthcare professional or lead-I ECG device algorithm (92%; 95% CI:
85% to 96%)[54] were similar to the sensitivity results reported for MPP in systematic reviews
(91.6%; 95% CI: 75% to 98.6%).[17] The specificity values for lead-I ECG traces interpreted by
a trained healthcare professional or lead-I ECG device algorithm were relatively higher (82%;
95% CI: 76% to 88%)[54] than those reported for MPP (78.8%; 95% CI: 51% to 94.5%).[17]
Table 4. Base Case 1: Incremental cost effectiveness analysis.
Strategy Costs QALYs Incremental costs Incremental QALYs ICER/ QALY gained
Standard pathway £514,187 447.963
Kardia Mobile £515,551 449.249 £1,364 1.286 £1,060
Generic lead-I device £516,730 449.246 £1,179 -0.002 Dominated
RhythmPad GP� £518,436 448.573 £2,885 -0.676 Dominated
Zenicor-ECG £518,468 449.199 £2,917 -0.050 Dominated
MyDiagnostick £521,233 449.024 £5,682 -0.225 Dominated
imPulse £530,745 448.987 £15,194 -0.262 Dominated
ICER = incremental cost effectiveness ratio; QALY = quality adjusted life year
�Algorithm interpretation
https://doi.org/10.1371/journal.pone.0226671.t004
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Lead-I ECG devices were more cost effective when there was a longer wait to 12-lead ECG
and if the 12-lead ECG is performed in hospital. The majority of the patient benefit, however,
comes after diagnosis due to a greater proportion of patients being correctly diagnosed with
and treated for AF when compared to the standard diagnostic pathway, even if this benefit is
slightly offset by an increased number of patients incorrectly diagnosed with AF with a lead-I
ECG device. The proportion of patients with paroxysmal AF is uncertain in this population. If
the proportion of patients with paroxysmal AF is lower than we assumed, lead-I ECG devices
would be less cost effective compared with the standard diagnostic pathway.
In line with our findings, the results of recently published economic evaluations[17, 55]
suggest that lead-I ECG devices may represent a cost effective use of resources for systematic,
opportunistic screening of people aged 65 years and over during a routine GP appointment.
Lead-I ECG devices may be cost effective for an asymptomatic population because only people
that have a positive lead-I ECG test will have a subsequent 12-lead ECG test carried out. If a
lead-I ECG test or an alternative screening test were not used, people with asymptomatic AF
would remain undiagnosed until the time of an event (e.g., stroke). People with asymptomatic
AF who are diagnosed early and receive appropriate treatment gain health benefits in compari-
son to people whose AF remains undiagnosed and who do not receive treatment for AF.
Currently, NICE recommends (CG180)[5] that an ECG is performed in all people (whether
symptomatic or not) in whom AF is suspected because an irregular pulse has been detected. In
updates to CG180[5] novel technologies to assist in the diagnosis of AF, such as lead-I ECG
devices, need to be clearly distinguished from 12-lead ECG devices.
The main limitation of our study is that there are no published data evaluating the diagnos-
tic accuracy, clinical impact or cost effectiveness of lead-I ECG devices for people presenting
to primary care with signs or symptoms of AF and an irregular pulse. However, using diagnos-
tic accuracy and clinical impact data from asymptomatic patients as a proxy, we present the
results of the first economic evaluation of lead-I ECG devices for people presenting to primary
care with signs or symptoms of AF and an irregular pulse; the economic evaluation considers
the pathways for patients with signs or symptoms of AF and an irregular pulse presenting to
the GP for an initial consultation.
Conclusions
There is no evidence available for the use of single-time point lead-I ECG devices for the detec-
tion of AF in people with signs or symptoms of AF and an irregular pulse. The results of this
assessment, using diagnostic accuracy data from asymptomatic patients as a proxy, suggest
that lead-I ECG devices represent a cost effective use of NHS resources compared with MPP
followed by a 12-lead ECG in primary or secondary care. The current standard pathway for
the diagnosis of AF shows that patients with signs or symptoms of AF and an irregular pulse
are advised to have a 12-lead ECG test. Given the assumptions in our model, the use of single-
time point lead-I ECG devices in primary care for the detection of AF in people with signs or
symptoms of AF and an irregular pulse appears to be a cost effective use of NHS resources
compared with MPP followed by a 12-lead ECG.
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